Annual reports executive summaries

FLUCOP Annual report Year 1

FLUCOP Annual report Year 2

FLUCOP Annual report Year 3



Dissemination material

To improve the toolbox available to evaluate seasonal flu vaccines, European public and private research institutions are joining together in FLUCOP, a 13,9M€ project funded by the Innovative Medicines Initiative (IMI). Please follow the link for reading the full press release.


FLUCOP_Press Release


The FLUCOP flyer shows the project at a quick glance: FLUCOP_Flyer




Impact of erythrocyte species on assays for influenza serology. Trombetta CM, Ulivieri C, Cox RJ, Remarque EJ, Centi C, Perini D, Piccini G, Rossi S, Marchi S, Montomoli E. J Prev Med Hyg. 2018 Mar 30;59(1):E1-E7. doi: 10.15167/2421-4248/jpmh2018.59.1.870


Antibody responses to influenza A/H1N1pdm09 virus after pandemic and seasonal influenza vaccination in healthcare workers: a five-year follow-up study. Trieu MC, Jul-Larsen Å, Sævik M, Madsen A, Nøstbakken JK, Zhou F, Skrede S, Cox RJ. Clin Infect Dis. 2018 Jun 9. doi: 10.1093/cid/ciy487


Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine. Tete SM, Jul-Larsen Å, Rostami S, Lunde THF, Søland H, Krammer F, Cox RJ. Vaccine. 2018 Apr 12;36(16):2213-2219. doi: 10.1016/j.vaccine.2018.02.022.


Immune responses after live attenuated influenza vaccination. Mohn KG, Smith I, Sjursen H, Cox RJ. Hum Vaccin Immunother. 2018 Mar 4;14(3):571-578. doi: 10.1080/21645515.2017.1377376.


Primary Human Influenza B Virus Infection Induces Cross-Lineage Hemagglutinin Stalk-Specific Antibodies Mediating Antibody-Dependent Cellular Cytoxicity. de Vries RD, Nieuwkoop NJ, van der Klis FRM, Koopmans MPG, Krammer F, Rimmelzwaan GF. J Infect Dis. 2017 Dec 27;217(1):3-11. doi: 10.1093/infdis/jix546.


Influenza virus-specific antibody dependent cellular cytoxicity induced by vaccination or natural infection. de Vries RD, Nieuwkoop NJ, Pronk M, de Bruin E, Leroux-Roels G, Huijskens EGW, van Binnendijk RS, Krammer F, Koopmans MPG, Rimmelzwaan GF. Vaccine. 2017 Jan 5;35(2):238-247. doi: 10.1016/j.vaccine.2016.11.082. Epub 2016 Nov 30.

Freidl GS, van den Ham HJ, Boni MF, de Bruin E, Koopmans MP. Changes in heterosubtypic antibody responses during the first year of the 2009 A(H1N1) influenza pandemic. Sci Rep. 6:20385. doi: 10.1038/srep20385, 2016 Feb 8.


Mohn KG, Cox RJ1, Tunheim G, Berdal JE, Hauge AG, Jul-Larsen Å; Norwegian Pandemic Group, Peters B, Oftung F, Jonassen CM, Mjaaland S5. Immune Responses in Acute and Convalescent Patients with Mild, Moderate and Severe Disease during the 2009 Influenza Pandemic in Norway. PLoS One 10(11):e0143281. doi: 10.1371/journal.pone.0143281. eCollection 2015, 2015 Nov 25.


Lartey S, Pathirana RD, Zhou F, Jul-Larsen Å, Montomoli E, Wood J, Cox RJ.  Single dose vaccination of the ASO3-adjuvanted A(H1N1)pdm09 monovalent vaccine in health care workers elicits homologous and cross-reactive cellular and humoral responses to H1N1 strains. Hum. Vaccin. Immunother. 2015;11(7):1654-62. doi: 10.1080/21645515.2015.1048939, 2015 May 26.


Sridhar S, Brokstad KA, Cox RJ. Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza Vaccines. Vaccines (Basel) 3(2):373-89. doi: 10.3390/vaccines3020373, 2015 Apr 24.